Aspen Aerogels, Inc. (NYSE:ASPN) Given Average Rating of “Buy” by Analysts

Shares of Aspen Aerogels, Inc. (NYSE:ASPN) have been assigned an average rating of “Buy” from the ten brokerages that are covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $28.70.

A number of research analysts have recently issued reports on the company. Piper Sandler cut their price target on Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Barclays reduced their target price on shares of Aspen Aerogels from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Aspen Aerogels in a report on Wednesday, October 16th. StockNews.com upgraded shares of Aspen Aerogels to a “sell” rating in a research note on Wednesday, November 13th. Finally, Roth Mkm lowered their target price on shares of Aspen Aerogels from $36.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, November 8th.

Aspen Aerogels Price Performance

NYSE ASPN opened at $11.90 on Thursday. The company has a market cap of $976.36 million, a PE ratio of 1,191.19 and a beta of 2.12. Aspen Aerogels has a 52-week low of $10.75 and a 52-week high of $33.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.48 and a current ratio of 2.93. The firm’s 50 day moving average price is $15.89 and its 200-day moving average price is $22.02.

Insider Activity at Aspen Aerogels

In related news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the sale, the chief executive officer now owns 483,640 shares in the company, valued at $14,523,709.20. This represents a 11.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Aspen Aerogels

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Lord Abbett & CO. LLC purchased a new stake in Aspen Aerogels during the third quarter worth $10,126,000. Oppenheimer & Co. Inc. boosted its stake in shares of Aspen Aerogels by 167.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 102,535 shares of the construction company’s stock worth $2,839,000 after acquiring an additional 64,154 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Aspen Aerogels during the 3rd quarter valued at about $1,342,000. Dakota Wealth Management purchased a new position in shares of Aspen Aerogels in the 3rd quarter valued at about $986,000. Finally, Rice Hall James & Associates LLC raised its holdings in Aspen Aerogels by 19.9% in the 3rd quarter. Rice Hall James & Associates LLC now owns 535,113 shares of the construction company’s stock worth $14,817,000 after purchasing an additional 88,711 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.